Solvay Develops Industry-First Specialized UV-C Stabilizers for the Protection of Polyolefin Surfaces

Solvay, a global market leader in specialty materials, has announced the development of an innovative new portfolio of UV-C stabilizers. They are designed for use in demanding hygiene applications, where polyolefin surfaces are treated with ultra-violet (UV) light of the UV-C spectrum (200-280 nm) to fight against COVID and hospital-acquired infections.

The new proprietary stabilization technology represents an important milestone for the polyolefin industry, as it is the first to address the risk of polyolefin degradation, discoloration and micro-crack formation, which is caused by frequent exposure to UV-C irradiation.

“Healthcare and other markets, such as aerospace and shared mobility, are increasingly using UV-C light to disinfect high-contact surfaces in an effort to combat pathogens, including coronaviruses,” says Sophie Poelmans, Global Marketing Manager for Polymer Additives at Solvay Materials. “Our new UV-C stabilization technology helps end-users achieve effective UV-C disinfection levels on surfaces made from polyolefins without compromising the performance of the material.”

UV-C radiation can deactivate microorganisms and has been scientifically proven to be effective against coronaviruses. However, the proven germicidal action of UV-C also exposes the treated surfaces to much higher ultraviolet energy than that covered by traditional UV-A and UV-B stabilizers, resulting in the potential for faster material degradation.

Solvay, a member of the International Ultraviolet Association (IUVA), has leveraged its extensive expertise in polymer additives to develop a technology that is purpose-engineered to enable the use of UV-C light as an anti-microbial disinfectant on polyolefin surfaces, while safely protecting them against UV-C induced degradation.

Solvay’s new UV-C stabilization technology is targeted at a wide range of polyolefin applications, including medical equipment in operation and patient rooms, aircraft and shared vehicle interiors, and sporting venues.

SourceSolvay

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.